181 related articles for article (PubMed ID: 15179553)
1. Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy.
Huland E; Heinzer H; Jörres RA; Loppow D; Huland H
Urologe A; 2004 Sep; 43 Suppl 3():S140-4. PubMed ID: 15179553
[TBL] [Abstract][Full Text] [Related]
2. [Regional immunotherapy of metastatic renal cell carcinoma].
Heinzer H; Huland E; Huland H
Urologe A; 2002 May; 41(3):239-48. PubMed ID: 12132273
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter].
Heinzer H; Huland E; Aalamian M; Huland H
Urologe A; 1999 Sep; 38(5):466-73. PubMed ID: 10501705
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation.
Loppow D; Huland E; Heinzer H; Grönke L; Magnussen H; Holz O; Jörres RA
Eur J Med Res; 2007 Nov; 12(11):556-62. PubMed ID: 18024264
[TBL] [Abstract][Full Text] [Related]
5. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
Huland E; Heinzer H; Huland H
Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
[TBL] [Abstract][Full Text] [Related]
6. [Inhaled immunotherapy for pulmonary metastases of renal cell cancer].
Lümmen G; Schenck M; Börgermann C; Eisenhardt A; Vom Dorp F; Sperling H; Rübben H
Urologe A; 2004 Apr; 43(4):457-61. PubMed ID: 15085267
[TBL] [Abstract][Full Text] [Related]
7. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
Huland E; Heinzer H; Huland H
J Cancer Res Clin Oncol; 1994; 120(4):221-8. PubMed ID: 8288676
[TBL] [Abstract][Full Text] [Related]
8. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of pulmonary metastatic renal cell carcinoma: success dependant on risk factors?
Huland E; Heinzer H; Huland H
Hepatogastroenterology; 1999 May; 46 Suppl 1():1257-62. PubMed ID: 10429971
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2).
Huland E; Heinzer H; Huland H
Anticancer Res; 1999; 19(4A):2679-83. PubMed ID: 10470219
[TBL] [Abstract][Full Text] [Related]
12. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience.
Huland E; Heinzer H; Mir TS; Huland H
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S98-105. PubMed ID: 9457403
[TBL] [Abstract][Full Text] [Related]
13. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
14. [Complete remission of pulmonary metastasis from renal cell carcinoma through inhalation therapy with Interleukin-2 after unsuccessful systemic immunochemotherapy].
Rohrmann K; Schleypen J; Adam C; Hofstetter A; Siebels M
Urologe A; 2004 Oct; 43(10):1271-4. PubMed ID: 15372156
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
19. Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2.
Esteban-González E; Carballido J; Navas V; Torregrosa Z; Muñoz A; de Mon MA;
Anticancer Drugs; 2007 Mar; 18(3):291-6. PubMed ID: 17264761
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
